Resource Library

NORD Financials

Published January 1, 2021

2020 Annual Report

Advocacy, Rare Cancer

NORD RareInsights^® Rare Cancer Facts

Regulatory, Research & Drug Development

Published January 1, 2011

FDA’s Flexibility in Regulating Therapies

Advocacy, Legislative Advocacy, Research & Drug Development

Study on Orphan Drug Costs & Use

Advocacy, Research & Drug Development

Orphan Drug Costs & Expenditures

Advocacy, Research & Drug Development, Understanding Rare Disease

NORD RareInsights^® 5 Myths About the ODA

Advocacy, Regulatory, Research & Drug Development

Orphan Drug Trends in the United States 2018

Advocacy, Research & Drug Development

Published December 18, 2018

Orphan Drugs in the United States: Exclusivity, Pricing and Treated Populations

COVID-19

NORD RareInsights^® COVID-19 Community Survey Infographic

COVID-19

NORD RareInsights^® COVID-19 Community Survey Report

COVID-19

NORD RareInsights^® COVID-19 Community Survey Report #2

Advocacy, Regulatory, Telehealth, Understanding Rare Disease

NORD RareInsights^® Ensuring Access to Telehealth for Rare Diseases

Advocacy, Research & Drug Development

Orphan Drugs in the United States: Rare Disease Innovation and Cost Trends Through 2019

Advocacy, Regulatory, Research & Drug Development

Orphan Drugs in the United States: An Examination of Patents and Orphan Drug Exclusivity

Regulatory, Research & Drug Development

Published June 1, 2021

FDA’S Accelerated Approval Pathway: A Rare Disease Perspective